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Abstract
3-Hydroxy-3-methylglutaryl-coenzyme A [HMG-CoA] reductase gene (Hmgcr) is a susceptibility gene for essential
hypertension. Sequencing of the Hmgcr locus in genetically hypertensive BPH (blood pressure high), genetically
hypotensive BPL (blood pressure low) and genetically normotensive BPN (blood pressure normal) mice yielded a number of
single nucleotide polymorphisms (SNPs). BPH/BPL/BPN Hmgcr promoter-luciferase reporter constructs were generated and
transfected into liver HepG2, ovarian CHO, kidney HEK-293 and neuronal N2A cells for functional characterization of the
promoter SNPs. The BPH-Hmgcr promoter showed significantly less activity than the BPL-Hmgcr promoter under basal as
well as nicotine/cholesterol-treated conditions. This finding was consistent with lower endogenous Hmgcr expression in
liver and lower plasma cholesterol in BPH mice. Transfection experiments using 59-promoter deletion constructs
(strategically made to assess the functional significance of each promoter SNP) and computational analysis predicted lower
binding affinities of transcription factors c-Fos, n-Myc and Max with the BPH-promoter as compared to the BPL-promoter.
Corroboratively, the BPH promoter-luciferase reporter construct co-transfected with expression plasmids of these
transcription factors displayed less pronounced augmentation of luciferase activity than the BPL construct, particularly at
lower amounts of transcription factor plasmids. Electrophoretic mobility shift assays also showed diminished interactions of
the BPH promoter with HepG2 nuclear proteins. Taken together, this study provides mechanistic basis for the differential
Hmgcr expression in these mouse models of human essential hypertension and have implications for better understanding
the role of this gene in regulation of blood pressure.
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Introduction
Essentialhypertension,the chiefriskfactor forcardiovascularand
renal diseases, is often associated with and complicated by
dyslipidemia [1,2]. 3-Hydroxy-3-methylglutaryl-coenzyme A
[HMG-CoA] reductase gene (Hmgcr/HMGCR) is a candidate gene
for hypertension; it translates to the rate-limiting enzyme in the
cholesterol biosynthesis pathway and cholesterol is the precursor of
glucocorticoid steroid hormones that play a profound role in blood
pressure homeostasis and hypertension [3–7]. Consistently, the G
allele of HMGCR rs17238540 (G/T) single nucleotide polymor-
phism [SNP] was associated with higher blood pressure [BP] and
higher stroke risk in an European population of ,23,000
participants [8]. Moreover, this SNP was associated with the BP
response to urinary sodium: potassium ratio [9] and response to
statin (inhibitor of HMGCR enzyme) therapy in terms of total
cholesteroland triglyceride lowering [10]. Twocommon and tightly
linkedHMGCRSNPswerealsosignificantlyassociatedwithreduced
efficacy of pravastatin therapy [11]. Additionally, investigations on
gene expression pattern in adrenal glands of two independent,
inbred,homozygousrodent modelsofhumanessentialhypertension
(viz. spontaneously hypertensive rat and blood pressure high [BPH]
mice) revealed ,2- to 3-fold over-expression of Hmgcr in these
strains as compared to their corresponding controls (viz. Wistar/
Kyoto rat and blood pressure low [BPL] mice) [12,13]. These
findings suggested the possibility that an altered Hmgcr expression
might be a systematic facet of hereditary hypertension in mammals,
perhaps even contributing to diverse metabolic abnormalities
associated with this common disorder. However, molecular basis
of the differential Hmgcr expression in these animal models has not
been studied. Hmgcr levels in other tissues (e.g., liver) of BPL and
BPH mice also remain unknown.
The hypertensive mouse strain BPH was developed in a breeding
program based solely on selection by elevated BP and it parallels
human hypertension [14]. The BPH strain exhibits many of the co-
morbidities observed in human hypertension, such as higher heart
rate, larger hearts and kidneys, higher left ventricular weight and
early mortality than the hypotensive BPL strain [14]. During
generation of the BPH and BPL strains, the normotensive inbred
strain BPN (blood pressure normal) was derived from the unselected
control population and this strain serves as a control for
hypertensive BPH and hypotensive BPL mice [14].
PLoS ONE | www.plosone.org 1 January 2011 | Volume 6 | Issue 1 | e16661In the present study, we sequenced the mouse Hmgcr locus
(proximal promoter, 20 exons and flanking intronic regions) in the
BPH, BPL and BPN strains and discovered several SNPs in
promoter and coding exonic regions. Next, we assessed the
quantitative impact of the promoter SNPs on Hmgcr gene
expression by computational as well as experimental analyses.
The results revealed that two promoter SNPs (C-874T and C-
740T) altered binding affinities of several transcription factors (n-
Myc, Max and c-Fos) and modulated Hmgcr expression in these
mouse models of human essential hypertension.
Materials and Methods
Ethics Statement/study approval
The present study was approved by the Institutional Biosafety
Committee at Indian Institute of Technology Madras (IIT
Madras), Chennai in June 2008.
Mouse strains and tissue samples
Liver tissue samples from 5–7 weeks old male BPH (strain
BPH/2J, at inbred generation F66) and BPL (strain BPL/1J, at
inbred generation F65) mice were collected in RNAlaterH solution
(Ambion, USA) at the Jackson Laboratory (Bar Harbor, USA;
www.jax.org) and shipped to our laboratory following institutional
norms. BPH males display ,120 mm systolic BP (SBP) while BPL
males display ,70 mm SBP at 4–15 weeks of age [14]. At 21
weeks of age, the SBP of BPH mice increases further to ,130 mm
while that of BPL remains almost unchanged [14]. We chose 5 to
7 weeks old mice for measurement of Hmgcr gene expression levels
because at that early age, BPH mice did not attain the maximal
elevation of BP. Therefore, studying these mice might allow us to
minimize the effects of aging-related confounding factors on Hmgcr
gene expression and increase the chance of detecting pathogenic
role for Hmgcr in hypertension.
Extraction of RNA and real-time PCR
Total RNA samples from liver tissues of four BPH and four BPL
mice were isolated using the TRIZOL reagent (Invitrogen, USA).
RNA concentrations were estimated by UV-spectrophotometry
(Eppendorf Biophotometer, Germany) and the integrity of RNA
molecules was assessed from the appearance of 28S and 18S bands
on agarose gels.
RNA samples were subjected to total cDNA synthesis by using the
ProtoScript Moloney Murine Leukemia Virus [M-MuLV] Taq RT-
PCR kit (New England Biolabs, USA) and the absence of genomic
DNA contamination was ascertained. See Text S1 for details.
Real-time PCR was carried out using the DyNAmo
TM HS
SYBRH Green qPCR Kit (Finnzymes, USA) and following Hmgcr
gene specific primers: forward, [+11763 bp] 59-CCCTGAGTT-
TAGCCTTCCTTTTG-39 [+11786 bp] and reverse, [+11880 bp]
59-GCTTTCTTTGAGGTCACGACGG-39 [+11858 bp]. For
normalization of Hmgcr expression, GAPDH and 18S rRNA
abundances were measured using the following primer pairs:
GAPDH forward, 59-CCTCGTCCCGTAGACAAAATG-39 and
GAPDH reverse, 59-TGAAGGGGTCGTTGATGGC-39 [15];
18S forward, 59-GTAACCCGTTGAACCCCATT -39 and 18S
reverse, 59-CCATCCAATCGGTAGTAGCG-39 [16]. See Text
Table 1. List of primers used for PCR amplification and sequencing of the Hmgcr gene in BPL, BPH and BPN mouse strains.
Target Forward Primer (nucleotide positions*) Reverse Primer (nucleotide positions*) Product size (bp)
Promoter PF (2961/2940): 59-CGGGGTACCTAAAGTGGGTAGGT-
ATATCCGG-39
PR (24/43): 59-CCGCTCGAGCTCACCTCCGGATCTCAATG-39 1004
Exon 1 1F (290/-70): 59-CGGACGATCCTTCCTTATTGG-39 1R (361/383): 59-TTTGCAGCCTACATCTCCATCAC-39 473
Exon 2 2F (3989/4008): 59-AAGAAGTGGCAAGCACCGTG-39 2R (4615/4593): 59-GAGAAAGCGTTCAAACAAGGACC-39 627
Exon 3 3F (4215/4238): 59-TGGGAAGTTATTGTGGGAACAGTG-39 3R (4783/4762): 59-CTGAAATCCAAAGTCTGCCAGC -39 569
Exon 4 4F (4798/4822): 59-AGTGTTGGGTTCATTCAGCAGTTAG-39 4R (5266/5245): 59-GGCAAAAAAGACTTGGCACAGC-39 469
Exon 5 5F (5885/5906): 59-AGCAGGAAAGTGGTCATGCCAC-39 5R (6221/6200): 59-GGGAAATGGGGAAGTGAGACAC-39 337
Exon 6 6F (7630/7653): 59-TCATGTAGGACCCAGGATGCTCTC-39 6R (7947/7923): 59-CCACACACTTACAATATCCCCGTTC-39 318
Exon 7 7F (10426/10446): 59-TTGTGCTGATGCTTGGGTCTG-39 7R (10886/10867): 59-ATGGCTGAGCTGCCAAATTG-39 461
Exon 8 8F (10655/10674): 59-TCGGCTGCATGTCAGTGTTG-39 8R (11030/11010): 59-CAAGCAAAAGCCCCCAAATAC-39 376
Exon 9 9F (11315/11338): 59-GGATGTTTGAACCCTTACAGCACC-39 9R(11924/11903): 59-TCCTTCTCACAAGCAGAGGCTC-39 610
Exon 10 10F (11481/11503): 59-TTGGTCCTTGTTCACGCTCATAG-39 10R (12138/12114): 59-CTCTGCTTGTAGTCTCTGCTTCCAC-39 658
Exon 11 11F (11982/12004): 59-CCGTGCTGTGTTCTTCATCTCAG-39 11R(12345/12322): 59-TCCTCTGTATTCTCCCCCAGTGTG-39 364
Exon 12 12F (13928/13949): 59-TGGGGCATAGTCTGGCTAAGTG-39 12R (14412/14389): 59-GAGCAAGCAAACAAACTGTTGGAC-39 485
Exon 13 13F (14663/14684): 59-CACTGATGAAGCCCTTGGTTTG-39 13R (15088/15067): 59-CTTGTGTCTGTCCCCGAATCTG-39 426
Exon 14 14F (14982/15003) FP: 59-GCAGAGCCATAAGCGTGAGTTG-39 14R (15546/15523): 59-CTTTTACCTGCTGAGCCACCTTAC-39 565
Exon 15 15F (15812/15832): 59-TCCATGCCTGAGAATGCCTTC-39 15R(16154/16131): 59-GGGTACGGTAGCACAGTTATGGTC-39 343
Exon 16 16F (17947/17969): 59-ACGGCTGCGTTACAACTGTTAAG-39 16R (18336/18313): 59-ATACCCACCCTGGCTTCAGACTTC-39 390
Exon 17-18 17F(18535/18559): 59-AGAGACAGAGCGGTAGATGTGAGTG-39 18R (19139/19116): 59-AGTCCCTGCCTTAACTTCCCTTAG-39 605
Exon 19 19F (19609/19629): 59-TTGCCACCAGCGTTTCTAATG-39 19R(19942/19921): 59-TCCAGGGCTTGGACTGAAGTTG-39 334
20aF (20136/20156): 59-CACATTCACATGCACCCCAAC-39 20aR(20949/20972): 59-GAGAGGTCCGACTTGCTTGTACTC-39 837
Exon 20 20bF (20726/20746): 59-TGCTGGTCTATTGATTGGGGG-39 20bR (21214/21235): 59-AACGAGCACTGTCTTCTCTGGC-39 510
20cF (20895/20918): 59-GCTGTGCCACACTCTGCACTAAAG-39 20cR (21603/21626): 59-TGACACAATCACTAAGAGGCTCCC-39 696
*The nucleotides were numbered upstream (2) or downstream (+) of the cap site.
doi:10.1371/journal.pone.0016661.t001
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PLoS ONE | www.plosone.org 2 January 2011 | Volume 6 | Issue 1 | e16661Figure 1. Schematic structure of the mouse Hmgcr gene. Exon/intron structure of the mouse Hmgcr gene (RefSeq NM_008255, from the UCSC
genome browser). The upstream ,1 kb promoter region and 20 exons spanning ,21.5 kb region of mouse chromosome 13 are shown. The exon/
intron lengths are not drawn to scale. Locations of the primers used for PCR-amplification and sequencing of Hmgcr genomic regions (upstream
promoter, exons, UTRs and exon-intron boundaries) of BPH, BPL and BPN mice are indicated by arrows. Sequences of the primers are given in Table 1.
doi:10.1371/journal.pone.0016661.g001
Table 2. Polymorphisms in the hmgcr gene in mouse models of essential hypertension.
Location of the SNP(nucleotide
position, region)* Mouse strains
Functional implication (alteration of transcription factor binding affinity
#/
amino acid residue)
BPN BPH BPL
2874 bp, promoter T C T Binding affinity of c-Fos is more for ‘‘T’’ as compared to ‘‘C’’
2740 bp, promoter C C T Binding affinity of n-Myc and Max is more for ‘‘T’’ than ‘‘C’’
2486 bp, promoter T DT T Deletion of one T from a 13 nucleotide polyT region
+4643 bp, exon 3 T A A Alteration of the amino acid Phenyl alanine (BPN) to Isoleucine (BPH and BPL) in the
trans-membrane region of the protein (at 62 residue position)
+4676 bp, exon 3 T A A Alteration of the amino acid Phenyl alanine (BPN) to Isoleucine (BPH and BPL), at the 73
residue position, in the trans-membrane region of the protein
+11531 bp, exon 9 A G G No change in the amino acid residue
+11577 bp, exon 9 A A G Alteration of the amino acid Asparagine (BPN and BPH) to Aspartate (BPL) at the 296
residue position, in the trans- membrane region of the protein
+12264 bp, exon 11 G A G Alteration of the amino acid Glutamic acid (BPN and BPL) to Lysine (BPH) at the 455
residue position, in the catalytic region of the protein
+15984 bp, exon 15 T G G Alteration of the amino acid Leucine (BPN) to Arginine (BPH and BPL) at the 645 residue
position, in the catalytic region of the protein
+18745 bp, exon 17 G T T Alteration of the amino acid Glycine (BPN) to Cysteine (BPH and BPL) at the 763 residue
position, in the catalytic region of the protein
+18849 bp, exon 18 G T T Alteration of the amino acid Lysine (BPN) to Asparagine (BPH and BPL) at the 770
residue position, in the catalytic region of the protein
+21205 bp, exon 20 (39-UTR) T C C -
+21410 bp, exon 20 (39-UTR) T C C -
+21446 bp, exon 20 (39-UTR) T C C -
*The numbering of the polymorphisms was done considering the first nucleotide of the Exon 1 as +1.
#The putative transcription factor binding sites and the binding affinity towards the promoter sequences harboring the polymorphisms were predicted using the
CONSITE web tool (http://asp.ii.uib.no:8090/cgi-bin/CONSITE/consite/).
doi:10.1371/journal.pone.0016661.t002
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by calculating the 2
(2DDCt) values [17].
Sequencing of mouse Hmgcr gene for polymorphism
discovery
Genomic DNA samples of BPL/1J, BPH/2J and BPN/3J mice
were obtained from the Jackson laboratory (Bar Harbor). Primers
were designed using the mouse Hmgcr reference sequence
NM_008255.2 (from the UCSC Genome Browser) to amplify
,1 kb promoter region, each of the 20 exons as well as 50–100 bp
of flanking intronic regions (Table 1 and Fig. 1). PCR was carried
out using Phusion
TM High-Fidelity DNA polymerase and dNTPs
from New England Biolabs, USA. Agarose-gel purified PCR
products served as templates for sequencing, with the exception
that purified PCR products inserted into the promoterless pGL3-
Basic vector (Promega, USA) were used for sequencing the
promoter region. DNA samples were sequenced using ABI 3130
Genetic Analyser and BigDye Terminator Cycle Sequencing
Ready Reaction Kit (Applied Biosystems, USA).
Construction of Hmgcr promoter-reporter plasmids
Approximately 1 kb Hmgcr promoter region was PCR-amplified
from BPH/BPL/BPN genomic DNA sample using the following
primers: forward, 59-CGGGGTACCTAAAGTGGGTAGGTA-
TATCCG-39 and reverse, 59-CCGCTCGAGCTCACCT-
CCGGATCTCAATGG-39 (with added KpnI and XhoI sites at
59 ends in forward and reverse primers respectively, shown in
bold). The amplified promoter fragments were inserted between
KpnI and XhoI sites in the firefly luciferase reporter vector pGL3-
Basic (Promega). Resulting plasmids were named as BPH-961,
BPL-961 and BPN-961, which contained 2961 bp to +43 bp
region of BPH, BPL and BPN Hmgcr (numberings are with respect
to the 1
st nucleotide of Exon 1 as +1). Similarly, the promoter-
reporter plasmids BPH-769, BPL-769 and BPN-769 (harbouring
Figure 2. Hmgcr promoter-SNPs alter potential binding affinities of promoter motifs with putative transcription factors. Pictorial
presentations as well as numerical nucleotide matrixes for c-Fos, n-Myc and Max binding motifs according to ConSite (http://asp.ii.uib.no:8090/cgi-
bin/CONSITE/consite) are shown. The 2881 to 2874 bp region of the mouse Hmgcr promoter contains a putative binding site for c-Fos while the
2744 to 2739 bp and 2747 to 2738 bp regions contain putative binding sites for n-Myc and Max respectively. The TRC single nucleotide
polymorphism (SNP) at 2874 bp alters the potential binding affinity of c-Fos to the promoter motif in BPL/BPN versus BPH, the ConSite scores being
3.933 vs. 2.994 (top panel). The TRC SNP at 2740 bp alters the potential binding affinity of n-Myc to the promoter motif in BPL versus BPN/BPH, the
ConSite scores being 6.038 vs. 4.171 (bottom panel, left). The TRC SNP at 2740 bp also alters the potential binding affinity of Max to the promoter
motif in BPL versus BPN/BPH, the ConSite scores being 7.054 vs. 2.925 (bottom panel, right).
doi:10.1371/journal.pone.0016661.g002
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amplified products in the pGL3-basic vector using the following
primers: forward, 59-CGGGGTACCAAACGCCAGAAGCA-
GAAGGTG-39 and reverse, 59-CCGCTCGAGCTCACC-
TCCGGATCTCAATGG-3’ (with added KpnI and XhoI sites in
forward and reverse primers respectively, shown in bold). We also
constructed the promoter reporter plasmids BPH-651, BPL-651
and BPN-651 (containing 2651 bp to +43 bp region) by digestion
of the BPH-961, BPL-961 and BPN-961 constructs with KpnI and
EcoRI (the EcoRI site is located at 2652/2647 bp position in the
Hmgcr promoter), excision of ,5.4 kb fragment from gel,
treatment with Mung Bean nuclease (New England Biolabs) to
remove overhangs and re-circularization with T4 DNA ligase
(New England Biolabs). The correct insertion/orientation and
existence of SNPs in cloned DNA fragments were confirmed by
sequencing of the entire inserts in several clones. The plasmids
were purified on columns using an endotoxin-free plasmid DNA
purification kit (Hi-Media, India) for transfection experiments.
Cell culture, transfection and reporter assay
Human hepatic cell line HepG2, Chinese hamster ovarian cell
line CHO, human embryonic kidney cell line HEK-293 and
mouse neuroblastoma cell line N2A were obtained from the
National Center for Cell Sciences, Pune, India. Cells were
cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) with
high glucose and GlutaMAX
TM-I (Invitrogen), supplemented with
10% fetal bovine serum (Invitrogen), penicillin G (100 U/ml) and
streptomycin sulfate (100 mg/ml) (Invitrogen) at 37uC with 6%
CO2. HepG2 and N2A cells (grown at 50–60% confluence in 12-
well plates) were transfected with 1 mg/well of promoter-reporter
plasmids using Lipofectamine-2000 (Invitrogen). Similarly grown
CHO and HEK-293 cells were transfected with 2 mg/well of
Figure 3. Expression of Hmgcr promoter- luciferase reporter plasmids in cultured cells. Panel A: Schematic presentation of Hmgcr
promoter-luciferase reporter constructs. The locations of promoter SNPs (at 2874, 2740 and 2486 bp) in BPH, BPL and BPN strains are indicated. DT
shows the deletion of T and 2961 indicates the length of promoter used in this study. Panels B and C: Comparison of Hmgcr promoter strengths
among BPH, BPL and BPN mice. Promoter reporter constructs harboring 2961 to +43 bp region of BPH/BPL/BPN Hmgcr gene were transfected to
HepG2 and CHO cells, along with the co-transfected control plasmid pCMV-bGal (b-galactosidase driven by CMV promoter). The cells were assayed
for luciferase and b-galactosidase activities 24–30 hrs after transfection. Values shown in the bar graph are the Means 6 S.E. of normalized (ratioed)
luciferase activity to the b-galactosidase activity from at least three independent experiments. The three strains’ transfected promoters displayed
significantly different activities in both HepG2 (ANOVA F=19.955, p,0.01) and CHO (ANOVA F=12.496, p,0.01) cells as determined by one-way
ANOVA with Tukey-Kramer multiple comparisons post-test. In general, the transfected BPL promoter was more active than the BPH promoter while
the BPN promoter displayed intermediate expression. (**) and (*) indicate p,0.01 and p,0.05 respectively, compared with BPL in the case of HepG2
cells and compared with BPH in the case of CHO cells.
doi:10.1371/journal.pone.0016661.g003
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control for transfection efficiency, cells were co-transfected with
0.5 mg/well of a b-galactosidase expression plasmid. Cells were
lysed 24–30 hours after transfection for reporter assays. The
luciferase assay was carried out with some modifications of a
previously described method [19,20]. The beta-gal assay was
carried out using ortho-nitrophenyl b-D-galactopyranoside as
substrate. See Text S1 for details.The results were expressed as
firefly luciferase/b-galactosidase activity.
To test the effect of nicotine on Hmgcr promoter activity, HepG2
and CHO cells transfected with promoter-reporter plasmids were
treated with various doses (100 mM to 1 mM) of nicotine bitartarate
(Sigma-Aldrich, USA) five hours after transfection and incubated
for 16–18 hrs. Likewise, to test the effect of cholesterol, cells were
grown in lipid-free DMEM medium (Hyclone-Thermo, USA) and
transfected cells were treated with 0.5 mg/ml of 25-hydroxycholes-
terol and 12 mg/ml cholesterol (Sigma-Aldrich) for 24–30 hrs. Cells
were treated with this mixture of sterols because although 25-
hydroxycholesterol was more potent than cholesterol in suppressing
reductaseactivity,butitcouldnotreplacecholesterolinmaintaining
the cell growth [21,22]. Cells were lysed and assayed for luciferase
activity as described above.
In some experiments, promoter-reporter constructs were co-
transfected with various transcription factor plasmids into CHO
cells: pmiw-nMyc expressing mouse n-Myc cDNA [23], pmiw-
Max expressing human Max cDNA [24] and pc-Fos expressing
mouse c-Fos cDNA [25]. In these co-transfection experiments, the
insert-free vectors pmiwSV (in case of n-Myc/Max) and pSGI (in
case of c-Fos) were used as balancing plasmids in different
transfection mixtures. As a control for varying cell number within
individual wells, total protein contents were measured in cell
lysates using Bradford’s assay reagent (Sigma-Aldrich). Luciferase
activities in cell lysates were expressed as relative light units
[RLU]/mg protein.
Electrophoretic mobility shift assay (EMSA)
Nuclear protein extracts from HepG2 cells were prepared using
the ProteoJET cytoplasmic and nuclear protein extraction kit
(Fermentas Life Sciences, USA) and stored in aliquots at 280uC
until use. See Text S1 for details.
The following oligos and their complementary strands were
obtained from Ocimum Biosolutions, India: BPH-nMyc/Max, 59-
GTGTAAGCACCCGAGAGTGGGA-3 (harboring C alelle at
the 2740 bp position, shown in bold); BPL-nMyc/Max, 59-
GTGTAAGCACCTGAGAGTGGGA -3 (harboring T allele at
the 2740 bp position, shown in bold); BPH-c-Fos, 59-GAAGGG-
TAAGTTACTCCAGGCTAACA-39 (harboring C allele at the -
874 bp position, shown in bold); BPL-c-Fos, 59- GAAGGG-
TAAGTTACTCTAGGCTAACA-39 (harboring T allele at the
2874 bp position, shown in bold) and the control primers nMyc/
Max-consensus, 59- GTGTAAGCACGTGAGAGTGGGA -39
(consensus n-Myc motif in bold) and c-Fos-consensus, 59-
GAAGGGTAAGTGAGTCAAGGCTAACA-39 (consensus c-
Fos motif in bold). These single stranded oligomers were
biotinylated using the Biotin 39 End Labeling kit (Pierce, USA)
and annealed. See Text S1 for details.
For EMSA, 10 mg of nuclear protein extract was incubated
with binding buffer [10 mM Tris, 50 mM KCl and 1 mM
dithiothreitol at pH 7.5], 50 ng/ml poly-dI-dC and 20 fmol of
biotinylated oligo for 20 min at room temperature. The reaction
mixtures were resolved on 1.5 mm thick 5% non-denaturing
polyacrylamide gels and transferred to nylon-66 membranes
(Fluka, USA). The DNA oligomers were UV cross-linked to
membrane at 312 nm for 10 min. The biotinylated probes were
detected by chemiluminescence using LightShift Chemilumines-
cent EMSA kit (Pierce).
Data presentation and statistics
Promoter/reporter transient transfections were carried out at
least three times and results were expressed as mean 6 S.E.
Statistical significance was calculated by student’s t-test and one-
way analysis of variance (ANOVA) with Tukey-Kramer multiple
comparisons post-test, as appropriate in different experiments
using the InStat 3 program (GraphPad software, USA).
Results
Discovery of polymorphisms in the mouse Hmgcr gene
Sequencing of the Hmgcr locus in BPH, BPL and BPN mice
yielded several SNPs (Table 2). In the promoter region, 3 SNPs
Figure 4. Endogenous Hmgcr expression in BPH and BPL liver tissues. Total RNA was extracted from liver tissues of BPH (n=4) and BPL
(n=4) mice and total cDNA was synthesized. Real-time PCR using the cDNA preparations were carried out with mouse Hmgcr specific primers as
described in the Materials and Methods. The Hmgcr mRNA levels among the samples were normalized by GAPDH (panel A) and 18S rRNA (panel B).
The Hmgcr mRNA abundance in BPL was significantly higher than BPH.
doi:10.1371/journal.pone.0016661.g004
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2486 bp (T/DT). Analysis of the sequences immediately
surrounding these promoter SNPs by ConSite (http://asp.ii.
uib.no:8090/cgi-bin/CONSITE/consite; [26]) for identification
of cis-regulatory elements revealed the presence of putative
binding sites for the transcription factors c-Fos (at -881 to
2874 bp), n-Myc (at 2744 to 2739 bp) and Max (=Myc-
associated factor X; at 2747 to 2738 bp). The 2874T variant
in BPL/BPN contributed to a better binding site than the
2874C variant in BPH for c-Fos (Fig. 2). Likewise, the 2740T
allele in BPL contributed to better binding sites for n-Myc and
Max than the 2740C allele in BPN/BPH (Fig. 2). The deletion
of T at 2486 bp in BPH did not alter any transcription factor
binding site.
In addition to the above-mentioned promoter variations, eight
SNPs in coding exons and three SNPs in the 39-UTR were
detected (Table 2). Seven of the exonic SNPs altered amino acid
residues and four of those belonged to the catalytic domain of the
Hmgcr enzyme. Of note, no SNP was detected in the 59-UTR
region and intronic regions flanking the exons.
Figure 5. Effect of nicotine on Hmgcr promoter expression. HepG2 and CHO Cells were transfected with BPL/BPH Hmgcr promoter (2961 to
+43 bp)/firefly luciferase construct. Transfected cells were treated with various doses of nicotine (100 mM, 200 mM and 1 mM) and incubated for 16–
18 hrs. Cells were lysed and assayed for luciferase activity and protein concentration. Results were expressed as Mean 6 S.E. of the ratio of firefly
luciferase activity/mg protein. Each experiment was performed in triplicate and repeated at least three times. Nicotine significantly induced the
expression of Hmgcr promoters in both HepG2 and CHO cells, to a greater extent in the case of BPL than BPH. (**) and (*) indicate p,0.01 and p,0.05
respectively, with respect to the mock (without stimulation).
doi:10.1371/journal.pone.0016661.g005
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To test functional implication of the Hmgcr promoter SNPs,
BPH/BPL/BPN promoter/luciferase reporter constructs (Fig. 3A)
were transfected into HepG2, CHO, HEK-293 and N2A cells. In
HepG2 cells, the BPL promoter activity was ,1.8-fold higher
(p,0.01) than the BPH promoter; the BPN promoter activity was
,1.4-fold less (p,0.05) than the BPL promoter (Fig. 3B).
Similarly, CHO cells showed ,1.5-fold higher (p,0.01) promoter
activity in the case of BPL than BPH; the BPN promoter was ,1.3
–fold more active (p,0.05) than the BPH promoter (Fig. 3C). In
HEK-293 cells, BPL and BPN promoter activities were ,1.4-fold
(p,0.01) and ,2.2-fold (p,0.01) respectively higher than the
BPH promoter activity (Table S1). In N2A cells, activities of the
BPL and BPN promoters were ,1.9-fold (p,0.01) and ,1.4-fold
(p,0.05) respectively higher than the BPH promoter (Table S1).
Thus, across these cell lines, in general, the BPL promoter was
more active than the BPH promoter while the BPN promoter
expression was intermediate.
Endogenous Hmgcr expression in BPH and BPL mice
To study whether endogenous Hmgcr expressions differ between
BPH and BPL mice in parallel to transfected promoter activities,
we measured Hmgcr mRNA levels in liver tissues by real-time PCR.
We chose liver tissues for this experiment because the liver is the
primary site of de novo cholesterol biosynthesis and an important
regulator of whole-body intermediary metabolism [27,28]. The
BPL liver samples showed significantly higher (,2.6-fold when
normalized to GAPDH, p=0.002; ,3.4-fold when normalized to
18S rRNA, p=0.022) level of Hmgcr mRNA than the BPH liver
samples (Fig. 4).
Augmentation of Hmgcr promoter activities by nicotinic
stumulation
Since nicotine administration augments cholesterol biosynthesis
[29–31], we tested the effect of nicotine (100 mM–1 mM) on BPH-
and BPL- Hmgcr promoters in cultured cells. Acute nicotine
treatment caused significantly dose-dependent induction of
promoter activities in both HepG2 (up to ,2.2-fold; Fig. 5A)
and CHO cells (up to ,1.7-fold; Fig. 5B). Similar to basal
expressions, BPL-promoter activities after nicotine were greater
than BPH at all nicotine doses. At the highest dose (1 mM) the
BPL vs. BPH promoter activities were: ,8.7610
5 RLU/mg
protein vs. ,4.1610
5 RLU/mg protein in HepG2 cells, p,0.01;
,4.7610
6 RLU/mg protein vs. ,3.6610
6 RLU/mg protein in
CHO cells, p,0.05; (Fig. 5).
Differential responses of Hmgcr promoters to
cholesterols
Sterols are known to negatively regulate Hmgcr expression as
well as enzyme activity [22,32,33]. Therefore, we tested the effect
of cholesterols on BPH- and BPL- Hmgcr promoter activities. Both
promoters displayed significant reductions in luciferase activities
with respect to corresponding basal values; the extent of down-
regulation was more pronounced in the case of BPL than BPH
(,77%, p,0.01 vs. ,53%, p,0.05 in HepG2 cells and ,49%,
p,0.01 vs. ,32%, p,0.05 in CHO cells; Fig. 6).
Functional characterization of the Hmgcr promoter SNPs
To assess the contribution of each Hmgcr promoter SNP towards
the differential expression of transfected BPH and BPL promoter/
reporter plasmids (Fig. 3), we undertook systematically progressive
deletion of the promoter region. First, we generated the BPH-769
and BPL-769 constructs (Fig. 7A) wherein the C-874T SNP was
excluded. Transfection of these constructs into HepG2 and CHO
cells showed that the BPL promoter was ,25–30% (p, 0.01)
more active than the BPH promoter (Fig. 7B and 7C).
Second, we generated the BPH-651 and BPL-651 constructs
(Fig. 8A) wherein the C-874T and C-740T SNPs were excluded.
Transfection of these constructs into HepG2 and CHO cells
displayed no significant difference in Hmgcr promoter activity
between BPH and BPL strains (Fig. 8B and 8C).
Taken together (Fig. 3, 7 and 8), while the 2486 (T/DT) SNP
did not influence promoter activity, the C-874T and C-740T
SNPs were functional and responsible for the higher Hmgcr
promoter activity in BPL than BPH. Consistently, the BPN-769
and BPH-769 constructs [that differed only at the 2486 (T/DT)
SNP position] did not display any difference in expression in
HepG2 and CHO cells (data not shown). Likewise, the BPN-651
promoter-reporter construct also did not show any difference in
luciferase activity as compared to BPL-651/BPH-651 construct in
HepG2 and CHO cells (data not shown).
The transcription factors c-Fos, n-Myc and Max modulate
Hmgcr expression
Since computational analysis of the promoter sequences around
the C-874T and C-740T SNPs predicted better binding affinity of
c-Fos, n-Myc and Max to the BPL promoter than the BPH
promoter (Fig. 2), we tested the effect of co-transfection of
expression plasmids of these transcription factors with BPL-/BPH-
promoter-reporter constructs in CHO cells. The BPL- and BPH-
promoters were differentially augmented by c-Fos/n-Myc/Max
(Fig. 9). At the lower dose (1.0 mg/well) of the transcription factors,
Figure 6. Effect of sterols on Hmgcr promoter expression.
HepG2 and CHO Cells cultured in lipoprotein-deficient medium were
transfected with BPL/BPH Hmgcr promoter (2961 to +43 bp)/firefly
luciferase construct. Transfected cells were treated with of 25-
Hydroxycholeserol (0.5 mg/ml) and of cholesterol (12 mg/ml) and
incubated for 24–30 hrs. Cells were lysed and assayed for luciferase
activity as well as protein concentration (for normalization). The
normalized Hmgcr promoter activity in response to sterols (as
percentage of control/basal) were expressed as Mean 6 S.E. Each
experiment was performed in triplicate and repeated at least three
times. Significant reduction in promoter activity was observed in both
HepG2 and CHO cells, to a greater extent in the case of BPL than BPH.
(**) and (*) indicate p,0.01 and p,0.05 respectively, with respect to
the mock (without stimulation).
doi:10.1371/journal.pone.0016661.g006
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were ,1.1-, ,2.0- and ,3.7–fold for c-Fos (Fig. 9A), n-Myc
(Fig. 9B) and Max (Fig. 9C) respectively. At the higher dose
(2.0 mg/well of c-Fos/n-Myc/Max), although no significant
difference in stimulation between BPL- and BPH- promoter was
observed in the case of n-Myc, the BPL-promoter activation was
still significantly more than the BPH-promoter in case of c-Fos
(,1.4-fold, p,0.01; Fig. 9A) and Max (,1.6-fold, p,0.01;
Fig. 9C).
Differential binding of nuclear proteins with BPL- and
BPH- Hmgcr promoter domains
To test whether the BPL- and BPH- Hmgcr promoter domains
harboring putative binding sites for c-Fos and n-Myc/Max
interact differently with HepG2 nuclear proteins, we carried out
EMSA experiments. The BPL c-Fos oligo (that contained a
better binding site for c-Fos) showed altered complex formation
pattern as compared to the BPH c-Fos oligo (Fig. 10A, lanes 8
and 9 vs. lanes 5 and 6). Likewise, the BPL n-Myc/Max oligo
(containing a better binding site for n-Myc/Max) yielded higher
amount of a specific nuclear protein-oligo complex than the
BPH n-Myc/Max oligo (Fig. 10B, lanes 8 and 9 vs. lanes 5 and
6). As a positive control, we tested complex formation using
consensus c-Fos oligo (Fig. 10A, lanes 2 and 3) and consensus n-
M y c / M a xo l i g o( F i g .1 0 B ,l a n e s2a n d3 ) .A sn e g a t i v ec o n t r o l s ,
when no nuclear extract was addedt ob i n d i n gr e a c t i o n s ,o n l y
labeled oligo bands were observed (Fig. 10A and 10B: lanes 1, 4
and 7).
Discussion
Mouse Hmgcr genetic polymorphisms
Several SNPs were discovered in the mouse Hmgcr gene
(Table 2). Two (C-874T and C-740T) of the 3 promoter SNPs
that distinguished BPL from BPH were transcriptionally active.
Alignment of the orthologous mammalian sequences around these
two SNP positions revealed that these promoter regions were
highly conserved (Fig. 11). The C allele at 2874 bp (present in
BPH) occurred in primates while the 2874T allele was found in
rodents (Fig. 11A). On the other hand, the C allele at 2740 bp
(present in BPH) occurred in rodents while the corresponding T
allele was found in primates (Fig. 11B).
Seven of the 8 exonic SNPs altered amino acid residues while one
was synonymous. Notably, two non-synonymous variations (Aspar-
tate296Asparagine in the trans-membrane region and Glutamic
acid455Lysine in the catalytic domain of the enzyme) distinguished
BPL from BPH. Interestingly, alignment of the orthologous
sequences around the non-synonymous SNPs revealed that while
the Hmgcr coding sequence was extremely conserved among
mammals (data not shown) amino acid variations discovered in
this study were unique to these strains excepting the BPL-
Aspartate296, which also occurred in rat (Fig. 11C). However, the
functional implications of these polymorphisms are not yet known.
Besides the promoter and 20 exons, we also sequenced the
exon-intron borders of the Hmgcr gene to probe for any alternative
splicing among these strains because a number of studies reported
variations in HMGCR exon/intron splicing in humans and CHO
Figure 7. Role of the C-740T and DT-486T SNPs in the differential activity of Hmgcr promoter. The BPH-769 and BPL-769 promoter/firefly
luciferase reporter constructs harboring C/T SNP at the 2740 bp position and DT/T SNP at the 2486 bp position (panel A) were generated as
described in the Materials and Methods section. These constructs were transfected into HepG2 and CHO cells, along with co-transfected b-
galactosidase expression plasmid. Cells were lysed 24–30 hrs after transfection and assayed for luciferase activity as well as b-galactosidase activity.
Values shown in the bar graph are the Means 6 S.E. of normalized luciferase activity (ratioed with respect to b-galactosidase activity) from at least
three independent experiments. The BPL promoter displayed significantly higher activity than the BPH promoter in HepG2 (panel B) and CHO cells
(panel C).
doi:10.1371/journal.pone.0016661.g007
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associated with inter-individual variation in plasma low-density
lipoprotein cholesterol response to statin treatment [34,35].
However, we did not find any interstrain variation in the
consensus splice donor (GU) or acceptor (AG) dinucleotides in
the Hmgcr introns.
Molecular basis of altered Hmgcr expression
Expression of promoter-reporter constructs in cultured cells
showed that the C-874T and C-740T SNPs were functional. The
2740T allele alone contributed to ,25–30% higher promoter
activity than the 2740C allele (Fig. 7 and 8); the 2740T and
2874T alleles together resulted in ,150–180% higher expression
of the BPL promoter than the BPH promoter (that contained the
2740C and 2874C alleles) (Fig. 3). Consistently, the BPN
promoter (that harboured the 2740C and 2874T alleles)
displayed intermediate activity (,125–135% as compared to the
BPH promoter; Fig. 3).
How might the C-874T and C-740T SNPs alter the Hmgcr
promoter activity? Computational analysis (by ConSite) revealed
that these T alleles offered better binding sites for c-Fos, n-Myc
and Max as compared to the C alleles (Fig. 2). Consistent with
these computational predictions, over-expression of c-Fos, n-Myc
and Max in CHO cells augmented the BPL-Hmgcr promoter
activity to a greater extent than the BPH-Hmgcr promoter (Fig. 9).
Interestingly, the extent of alteration of the promoter expression
by c-Fos/n-Myc/Max paralleled with the differences in ConSite
score (an index of binding affinity of a transcription factor
protein with a DNA motif) between the motifs for BPL and BPH.
For example, among these three proteins, the difference in
ConSite score was the highest between BPL-Max and BPH-Max
motifs (7.054–2.925<4 units) and the least between BPL-c-Fos
and BPH-c-Fos motifs (3.933–2.994<1 unit); Max co-expression
resulted in more dramatic differences between BPH and BPL
promoter activity while the c-Fos co-expression showed the least
difference in promoter activities, especially at the lower doses of
the transcription factor plasmid (Fig. 9). In addition, EMSA
experiments also showed enhanced complex formation of
HepG2 nuclear proteins with the BPL c-Fos/n-Myc/Max oligos
than the BPH c-Fos/n-Myc/Max oligos (Fig. 10) confirming
roles of the promoter variants in the differential Hmgcr gene
expression.
Of note, c-Fos, a basic leucine zipper (bZIP) protein and a
major component of the activator protein-1 transcription factor
complex, has been implicated as a regulator of cell proliferation,
differentiation and transformation [40–42]. A recent study
reported recruitment of c-Fos to the Hmgcr promoter for
transcriptional regulation under acute kidney injury in mice
[43]. The transcription factor n-Myc is a basic helix-loop-helix
leucine zipper (bHLH-ZIP) protein that heterodimerizes with the
transcription factor Max and play important roles in neuronal
differentiation and cell proliferation [44–48]. Although n-Myc and
Max have been reported to regulate transcription of many genes
[49–53], this study, for the first time, provides evidence for
regulation of the Hmgcr gene by these transcription factors.
Differential regulation of Hmgcr promoters by nicotine
and cholesterols
Nicotine caused dose-dependent activation of BPL and BPH
promoters in both HepG2 and CHO cells; the effect was more
Figure 8. The DT-486T SNP in the mouse Hmgcr promoter is not functional. The BPH-651 and BPL-651 promoter/firefly luciferase reporter
constructs harboring DT/T SNP at the -486 bp position (panel A) were generated as described in the Materials and Methods section. These constructs
were transfected into HepG2 and CHO cells, along with co-transfected b-galactosidase expression plasmid. Cells were lysed 24–30 hrs after
transfection and assayed for luciferase activity as well as b-galactosidase activity. Values shown in the bar graph are the Means 6 S.E. of normalized
luciferase activity (ratioed with respect to b-galactosidase activity) from at least three independent experiments. No difference in the activity between
the BPH and BPL promoter was observed in HepG2 (panel B) and CHO cells (panel C).
doi:10.1371/journal.pone.0016661.g008
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nicotinic acetylcholine receptors (nAChRs) in these cell types to
elicit nicotine-induced Hmgcr promoter stimulation? In isolated rat
hepatocytes, nicotine increased intracellular calcium concentration
and this phenomenon was blocked by d-tubocurarine, a nAChR
antagonist [54]. A recent study also detected the presence of alpha-
7 nAChRs in mouse liver by utilizing two carbon-11-labeled
alpha-7 nAChR agonists [55]. On the other hand, whereas the
presence of a7, a4o rb2 subunits of nAChR in CHO cells could
not be detected [56], the existence of an intraovarian, non-
Figure 9. Activation of Hmgcr promoter activity by over-expression of c-Fos, n-Myc and Max. CHO cells were transiently transfected with
increasing quantities (0–2.0 mg/well) of expression plasmids for the transcription factors c-Fos (Panel A), n-Myc (Panel B) or Max (Panel C) and 1.0 mg/
well of BPL/BPH Hmgcr promoter (2961 to +43 bp)/firefly luciferase construct in 12-well cell culture plates. The total amount of plasmid DNA
transfected to each well was made equal by using balancing amounts of the backbone plasmids (viz. pMiwSV plasmid in the cases of n-Myc/Max co-
transfection and pSGI plasmid in the case of c-Fos co-transfection). Cells were lysed 24–30 hrs after transfection and assayed for luciferase activity.
The results are expressed as ratios of firefly luciferase activity/mg protein and are the mean 6 SE (n=3–4 transfections for each construct). Although
both BPL and BPH promoters displayed, in general, activation by each of these three transcription factors in a dose-dependent manner with respect
to the control, the extents of activations were greater in case of BPL. (**) and (*) indicate p,0.01 and p,0.05 respectively with respect to the
corresponding mock (i.e., without a co-transfected transcription factor). Co-transfection of Max expression plasmid resulted in more dramatic
difference in promoter activities between BPL and BPH while the c-Fos expression plasmid showed the least difference in promoter activities,
especially at the equimolar dose (1.0 mg/well transcription factor along with 1.0 mg/well promoter/reporter).
doi:10.1371/journal.pone.0016661.g009
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[57,58]. In view of these reports, we speculate that the nicotinic
stimulation of Hmgcr promoter in HepG2 and CHO may be
mediated by some nAchR subtype(s). Further studies are required
to establish the mechanism of nicotinic signal transduction in these
cells.
The differential nicotinic activation of Hmgcr promoters may be
mediated by altered interaction of the c-Fos/n-Myc motifs in cis
with c-Fos and n-Myc in trans since these BPH- and BPL- promoter
motifs have different binding affinities with these nuclear proteins
(Fig. 2 and 10). Notably, several studies have shown that nicotine
regulates expression of c-Fos and Myc in different cell types [59–
62]. The different extent of nicotinic stimulation of the Hmgcr
promoters may also be contributed by the transcription factor
cyclic AMP response element binding protein (CREB) because
nicotine is known to activate the phosphorylation of CREB, which
induces the expression its early target c-Fos [63,64]. Thus, our
initial findings indicate hitherto un-described involvement of
several transcription factors in nicotine-evoked activation of Hmgcr
transcription and hence their possible roles in nicotinic modulation
of cholesterol biosynthesis. However, further studies are required
to confirm the contribution of these transcription factors in the up-
regulation of Hmgcr expression by nicotine.
Similar to nicotine, the BPL- and BPH- Hmgcr promoters
responded differentially to cholesterols, albeit the effect was down-
regulation of gene expression; BPL-promoter showed more
pronounced repression of the luciferase activity than the BPH-
promoter (Fig. 6). What might be the molecular mechanism for
this differential response by these promoters? Although the
identities of the transcription factors involved in the sterol
regulation of Hmgcr promoter still remain incompletely under-
stood, previous studies demonstrated important roles for the sterol
regulatory element (SRE-1) SRE binding proteins (SREBPs),
CCAAT-binding factor/nuclear factor-Y (CBF/NF-Y) and CREB
[65–68]. Since the BPL- and BPH- Hmgcr did not differ at the
SRE-1 or CBF/NF-Y or CRE motifs and the differential
expression under the basal conditions was mediated by c-Fos/n-
Myc/Max (Fig. 2, 9, 10), the greater sterol-repression (i.e. negative
feedback regulation) of the BPL- promoter may be modulated by
interaction of SREBP/CBF/NF-Y/CREB with c-Fos/n-Myc/
Max. Of note, 25-hydroxycholesterol has been reported to cause
calcium-dependent activation of c-Fos via the ERK1/2 signaling
pathway in monocytic THP-1 cells [69]. Further studies are
required to unravel the possible regulatory role of c-Fos/n-Myc/
Max in repression of Hmgcr expression by cholesterols.
Hmgcr endogenous gene expression studies: possible
mechanisms for differential transcript abundance
Tissue distribution pattern of the Hmgcr gene showed a high
level of expression in the liver [70]. Consistently, the Hmgcr
protein level was reported to be 4- to 6 -fold higher in the liver
than most peripheral tissues [27]. In this study, we measured the
abundance of Hmgcr transcripts in BPH and BPL liver tissues and
detected as much as ,3.4-fold higher expression in BPL (Fig. 4).
Intriguingly, such a large magnitude Hmgcr over-expression in BPL
liver cannot be accounted for by functional promoter variants
alone because the transfected BPL promoter showed only up to
,1.8-fold higher activity than the BPH promoter in HepG2 cells
(Fig. 3). Other genetic and/epigenetic factors may, therefore, also
contribute to the difference in the endogenous Hmgcr expression in
these mouse models. However, the higher Hmgcr expression in
BPL is consistent with the elevated hepatic cholesterols (,1.4-fold,
p=0.025) and plasma cholesterols (,1.3-fold, p,0.01) in these
Figure 10. Electrophoretic mobility shift assays demonstrating
complex formation between Hmgcr promoter domains and
HepG2 nuclear proteins. Panel A: Oligos harboring the consensus c-
Fos motif and the BPL-/BPH- Hmgcr promoter c-Fos motifs were
biotinylated and incubated with HepG2 nuclear extracts as described in
the Materials and Methods section. The BPL c-Fos oligo displayed
dramatically enhanced formation a specific nuclear protein–oligo
complex (lanes 8 and 9; indicated by a horizontal arrow) as compared
to the BPH c-Fos oligo (lanes 5 and 6). As a negative control, no nuclear
extract was added in some of the reactions (lane 1, consensus c-Fos
oligo; lane 4, BPH c-Fos oligo; lane 7, BPL c-Fos oligo) to visualize the
location of free/unbound probes on the gel. As a positive control,
complexes formed by the consensus c-Fos oligo are shown in lanes 2
and 3. The results are representative of at least three separate
experiments. Panel B: Oligos harboring the consensus n-Myc/Max
motif and the BPL/BPH- Hmgcr promoter n-Myc/Max motifs were
biotinylated and incubated with HepG2 nuclear extracts as described in
the Materials and Methods section. The BPL n-Myc/Max oligo displayed
formation of significantly higher amount of a specific nuclear protein–
oligo complex (lanes 8 and 9; indicated by a horizontal arrow) as
compared to the BPH n-Myc/Max oligo (lanes 5 and 6). As a negative
control, no nuclear extract was added in some of the reactions (lane 1,
consensus n-Myc/Max oligo; lane 4, BPH n-Myc/Max oligo; lane 7, BPL n-
Myc/Max oligo) to visualize the location of free/unbound probes on the
gel. As a positive control, complexes formed by the consensus n-Myc/
Max oligo are shown in lanes 2 and 3. The results are representative of
at least three separate experiments.
doi:10.1371/journal.pone.0016661.g010
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Jackson Laboratory; ,www.jax.org/phenome.).
Of note, in an earlier genome-wide transcriptome profiling
study in adrenal glands, BPH mice displayed ,3-fold higher Hmgcr
expression than BPL mice [12]. What might be the mechanism of
such directionally opposite differential Hmgcr expression between
liver and adrenal glands in these mice? Given that in both these
studies, BPL and BPH mice of similar age (5-7 weeks old) and
same sex (male) were used, the altered Hmgcr expression might be
caused/contributed by other factors. For example, Hmgcr expres-
sion in these strains might occur in a tissue-specific manner,
perhaps mediated by specific transcription factors in liver versus
adrenals tissues, as reported in the cases of human and rat
orthologues of Hmgcr as well as other genes [19,71–76]. Further,
the concentration of cholesterol in the plasma reflects the net
contribution of cholesterol synthesis, secretion, and absorption
from various tissues, including the liver and adrenal glands [77].
Although extrahepatic tissues also have local cholesterol biosyn-
thesis systems [78–80], the cholesterol needs of several tissues are
mainly met by receptor-mediated uptake of low-density lipopro-
tein from the circulation [32]. Notably, in female rats, the highest
rate of uptake of sterols was found in adrenal glands where only
4% of the tissue sterol content came from local synthesis [81]. In
BPH mice, the supply of low-density lipoprotein cholesterol to the
extrahepatic tissues including adrenals might be insufficient due to
lower circulating cholesterol in this strain. Therefore, the
Figure 11. Conservation of Hmgcr sequences among mammalian species. Alignment of orthologous sequences around the promoter
polymorphisms C-874T (panel A), C-740T (panel B) and the amino acid variant N296D (panel C) in mouse Hmgcr was carried out using Clustal W. The
promoter as well as protein sequences were found to be highly conserved among the mammals. The binding motifs for the transcription factors c-
Fos (panel A) and n-Myc/Max (panel B) are shown within brackets. The BPH, BPL and BPN sequences were determined in this study (as described in
the Materials and Methods section) while the other sequences were obtained from UCSC/NCBI public databases; the accession numbers for the
promoter sequences are: human, NM_000859.2; chimpanzee, XM_001148324.1; rhesus monkey, XM_001104607.2; rat, NM_013134.2, and the
accession numbers for the amino acids sequences are: human, NP_000850.1; chimpanzee, XP_001148324.1; rhesus monkey, XP_001104607.1; rat,
NP_037266.2). The positions of the nucleotide/amino acid variations are indicated by upward arrows.
doi:10.1371/journal.pone.0016661.g011
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place to increase de novo cholesterol synthesis in order to meet the
local sterol-demand.
Thus, the BPH mouse appears as a unique model where the
dyslipidemia and hypertension are not inter-connected. Given that
these genetically hypertensive mice were derived solely based on
high BP phenotype [14], this phenomenon might be caused/
contributed by segregation of genes. However, such dissociation
between severe hypertension and enhanced lipid synthesis in this
model may yield important insights into factors that govern the
coupling of these traits in humans. Interestingly, this is reminiscent
of the recent findings on chromogranin A gene knockout mice,
which displayed severe hypertension but unaltered plasma
cholesterol level as compared to wild type mice [82].
Concluding remarks
The present study unfolded the quantitative impact of two
Hmgcr promoter SNPs on gene expression in three mouse models
of human essential hypertension. The functional implication of
these SNPs for hypertension remains to be elucidated. Further
investigations are also required to unravel the qualitative impact of
non-synonymous SNPs (especially those in the catalytic region).
Nonetheless, this is the first report on identification and molecular
characterization of functional polymorphisms at the Hmgcr locus in
genetically hypertensive versus genetically hypotensive mice.
Future studies may establish additional genetic and molecular
links of the Hmgcr gene to hypertension and associated cardiovas-
cular disease states.
Supporting Information
Text S1 Supplementary methods.
(DOC)
Table S1 Basal expression of Hmgcr promoter-lucifer-
ase reporter plasmids in cultured cells.
(DOC)
Acknowledgements
The authors are thankful to Dr. Hisato Kondoh, Osaka University, Japan
for providing them with the n-Myc and Max expression plasmids as well as
the insert-free vector pmiwSV, and to Dr. Vijay Kumar, International
Centre for Genetic Engineering and Biotechnology, New Delhi, India for
the c-Fos expression plasmid as well as the corresponding insert-less vector
pSGI. The authors would also like to express their gratitude to Dr. D.
Karunagaran, Dr. Amal K. Bera, Dr. Madhulika Dixit and Dr. S.
Mahalingam of the Department of Biotechnology, IIT Madras for helping
them in various ways.
Author Contributions
Conceived and designed the experiments: PJS BSS BKS NRM. Performed
the experiments: PJS BSS BKS GL PG. Analyzed the data: PJS BSS BKS
NRM. Contributed reagents/materials/analysis tools: PJS BKS NRM.
Wrote the paper: PJS NRM.
References
1. Chapman MJ, Sposito AC (2008) Hypertension and dyslipidaemia in obesity
and insulin resistance: Pathophysiology, impact on atherosclerotic disease and
pharmacotherapy. Pharmacol Ther 117: 354–373.
2. Mule ´ G, Cottone S, Nardi E, Andronico G, Cerasola G (2006) Metabolic
syndrome in subjects with essential hypertension: relationships with subclinical
cardiovascular and renal damage. Minerva Cardioangiol 54: 173–194.
3. Xu J, Lecanu L, Han Z, Yao Z, Greeson J, et al. (2003) Inhibition of Adrenal
Cortical Steroid Formation by Procaine Is Mediated by Reduction of the cAMP-
Induced 3-Hydroxy-3-methylglutaryl-coenzyme A Reductase Messenger Ribo-
nucleic Acid Levels. J Pharmacol Exp Ther 307: 1148–1157.
4. Ardekani AM, Walker SJ, Donohue SJ, Stitzel RE, Connors JM, et al. (1989)
Adrenocorticotropin and corticosterone levels in pre-weanling spontaneously
hypertensive rats. Life Sci 44: 919–925.
5. Hashimoto K, Makino S, Hirasawa R, Takao T, Sugawara M, et al. (1989)
Abnormalities in the Hypothalamo-Pituitary-Adrenal Axis in Spontaneously
Hypertensive Rats during Development of Hypertension. Endocrinology 125:
1161–1167.
6. Lim HH, DeLano FA, Schmid-Schonbein GW (2001) Life and Death Cell
Labeling in the Microcirculation of the Spontaneously Hypertensive Rat. J Vasc
Res 38: 228–236.
7. Walker BR, Best R, Shackleton CHL, Padfield PL, Edwards CRW (1996)
Increased Vasoconstrictor Sensitivity to Glucocorticoids in Essential Hyperten-
sion. Hypertension 27: 190–196.
8. Freitas RN, Khaw KT, Wu K, Bowman R, Jeffery H, et al. (2010) HMGCR
gene polymorphism is associated with stroke risk in the EPIC-Norfolk study.
Eur J Cardiovasc Prev Rehabil 17: 89–93.
9. Freitas RN, Khaw KT, Wu K, Bowman R, Jeffery H, et al. (2009) A HMGCR
polymorphism is associated with relations between blood pressure and urinary
sodium and potassium ratio in the Epic-Norfolk Study. J Am Soc Hypertens 3:
238–244.
10. Donnelly LA, Doney AS, Dannfald J, Whitley AL, Lang CC, et al. (2008) A
paucimorphic variant in the HMG-CoA reductase gene is associated with lipid-
lowering response to statin treatment in diabetes: a GoDARTS study.
Pharmacogenet Genomics 18: 1021–1026.
11. Chasman DI, Posada D, Subrahmanyan L, Cook NR, Stanton VPJ, et al. (2004)
Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA 291:
2821–2827.
12. Friese RS, Mahboubi P, Mahapatra NR, Mahata SK, Schork NJ, et al. (2005)
Common genetic mechanisms of blood pressure elevation in two independent
rodent models of human essential hypertension. Am J Hypertens 18: 633–652.
13. Fries RS, Mahboubi P, Mahapatra NR, Mahata SK, Schork NJ, et al. (2004)
Neuroendocrine Transcriptome in Genetic Hypertension: Multiple Changes in
Diverse Adrenal Physiological Systems. Hypertension 43: 1301–1311.
14. Schlager G, Sides J (1997) Characterization of hypertensive and hypotensive
inbred strains of mice. Lab Anim Sci 47: 288–292.
15. Wang F, Wang J, Liu D, Su Y (2010) Normalizing genes for real-time
polymerase chain reaction in epithelial and nonepithelial cells of mouse small
intestine. Anal Biochem 399: 211–217.
16. Schmittgen TD, Zakrajsek BA (2000) Effect of experimental treatment on
housekeeping gene expression: validation by real-time, quantitative RT-PCR.
J Biochem Biophys Methods 46: 69–81.
17. Livak KJ, Schmittgen TD (2001) Analysis of Relative Gene Expression Data
Using Real-Time Quantitative PCR and the 2-[Delta][Delta]CT Method.
Methods 25: 402–408.
18. Jordan M, Wurm F (2004) Transfection of adherent and suspended cells by
calcium phosphate. Methods 33: 136–143.
19. Mahapatra NR, Mahata M, Ghosh S, Gayen JR, O’Connor DT, et al. (2006)
Molecular basis of neuroendocrine cell type-specific expression of the
chromogranin B gene: crucial role of the transcription factors CREB, AP-2,
Egr-1 and Sp1. J Neurochem 99: 119–133.
20. Mahapatra NR, Mahata M, O’Connor DT, Mahata SK (2003) Secretin
Activation of Chromogranin A Gene Transcription. J Biol Chem 278:
19986–19994.
21. Brown MS, Goldstein JL (1974) Suppression of 3-Hydroxy-3-methylglutaryl
Coenzyme A Reductase Activity and Inhibition of Growth of Human
Fibroblasts by 7-Ketocholesterol. J Biol Chem 249: 7306–7314.
22. Chin DJ, Gil G, Faust JR, Goldstein JL, Brown MS, et al. (1985) Sterols
accelerate degradation of hamster 3-hydroxy-3-methylglutaryl coenzyme A
reductase encoded by a constitutively expressed cDNA. Mol Cell Biol 5:
634–641.
23. Kato K, Kanamori A, Kondoh H (1990) Rapid and transient decrease of N-myc
expression in retinoic acid-induced differentiation of OTF9 teratocarcinoma
stem cells. Mol Cell Biol 10: 486–491.
24. Tsuneoka M, Nakano F, Ohgusu H, Mekada E (1997) c-myc activates RCC1
gene expression through E-box elements. Oncogene 14: 2301–2311.
25. Kalra N, Kumar V (2004) c-Fos Is a Mediator of the c-Myc-induced Apoptotic
Signaling in Serum-deprived Hepatoma Cells via the p38 Mitogen-activated
Protein Kinase Pathway. J Biol Chem 279: 25313–25319.
26. Sandelin A, Wasserman WW, Lenhard B (2004) ConSite: web-based prediction
of regulatory elements using cross-species comparison. Nucl Acids Res 32:
W249–252.
27. Tam SP, Brissette L, Ramharack R, Deeley RG (1991) Differences between the
regulation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase and low density
lipoprotein receptor in human hepatoma cells and fibroblasts reside primarily at
the translational and post-translational levels. J Biol Chem 266: 16764–
16773.
Hmgcr Polymorphisms Regulate Gene Expression
PLoS ONE | www.plosone.org 14 January 2011 | Volume 6 | Issue 1 | e1666128. Dietschy JM, Turley SD, Spady DK (1993) Role of liver in the maintenance of
cholesterol and low density lipoprotein homeostasis in different animal species,
including humans. J Lipid Res 34: 1637–1659.
29. Latha MS, Vijayammal PL, Kurup PA (1993) Effect of nicotine administration
on lipid metabolism in rats. Indian J Med Res 98: 44–49.
30. Chattopadhyay K, Chattopadhyay BD (2008) Effect of nicotine on lipid profile,
peroxidation & antioxidant enzymes in female rats with restricted dietary
protein. Indian J Med Res 27: 571–576.
31. Jarvis CM, Hayman LL, Braun LT, Schwertz DW, Ferrans CE, et al. (2007)
Cardiovascular Risk Factors and Metabolic Syndrome in Alcohol- and Nicotine-
Dependent Men and Women. J Cardiovasc Nurs 22: 429–435.
32. Brown MS, Goldstein JL (1986) A receptor-mediated pathway for cholesterol
homeostasis. Science 232: 34–47.
33. Busch SJ, Barnhart RL, Martin GA, Flanagan MA, Jackson RL (1990)
Differential regulation of hepatic triglyceride lipase and 3-hydroxy-3-methylglu-
taryl-CoA reductase gene expression in a human hepatoma cell line, HepG2.
J Biol Chem 265: 22474–22479.
34. Medina MW, Gao F, Ruan W, Rotter JI, Krauss RM (2008) Alternative Splicing
of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Is Associated With
Plasma Low-Density Lipoprotein Cholesterol Response to Simvastatin. Circu-
lation 118: 355–362.
35. Burkhardt R, Kenny EE, Lowe JK, Birkeland A, Josowitz R, et al. (2008)
Common SNPs in HMGCR in Micronesians and Whites Associated With LDL-
Cholesterol Levels Affect Alternative Splicing of Exon13. Arterioscler Thromb
Vasc Biol 28: 2078–2084.
36. Medina MW (2010) The Relationship Between HMGCR Genetic Variation,
Alternative Splicing, and Statin Efficacy. Discov Med 9: 495–499.
37. Engfelt WH, Masuda KR, Paton VG, Krisans SK (1998) Splice donor site
mutations in the 3-hydroxy-3-methylglutaryl coenzyme A reductase gene cause a
deficiency of the endoplasmic reticulum 3-hydroxy-3-methylglutaryl coenzyme
A reductase protein in UT2 cells. J Lipid Res 39: 2182–2191.
38. Luskey KL (1987) Conservation of promoter sequence but not complex intron
splicing pattern in human and hamster genes for 3-hydroxy-3-methylglutaryl
coenzyme A reductase. Mol Cell Biol 7: 1881–1893.
39. Reynolds GA, Goldstein JL, Brown MS (1985) Multiple mRNAs for 3-hydroxy-
3-methylglutaryl coenzyme A reductase determined by multiple transcription
initiation sites and intron splicing sites in the 59-untranslated region. J Biol Chem
260: 10369–10377.
40. Glover JNM, Harrison SC (1995) Crystal structure of the heterodimeric bZIP
transcription factor c-Fos-c-Jun bound to DNA. Nature 373: 257–261.
41. Dony C, Gruss P (1987) Proto-oncogene c-fos expression in growth regions of
fetal bone and mesodermal web tissue. Nature 328: 711–714.
42. Grigoriadis AE, Wang ZQ, Cecchini MG, Hofstetter W, Felix R, et al. (1994) c-
Fos: a key regulator of osteoclast-macrophage lineage determination and bone
remodeling. Science 266: 443–448.
43. Naito M, Bomsztyk K, Zager RA (2009) Renal Ischemia-Induced Cholesterol
Loading: Transcription Factor Recruitment and Chromatin Remodeling along
the HMG CoA Reductase Gene. Am J Pathol 174: 54–62.
44. Blackwood EM, Eisenman RN (1991) Max: a helix-loop-helix zipper protein
that forms a sequence-specific DNA-binding complex with Myc. Science 251:
1211–1217.
45. Cole MD, McMahon SB (1999) The Myc oncoprotein: a critical evaluation of
transactivation and target gene regulation. Oncogene 18: 2916–2924.
46. Wenzel A, Cziepluch C, Hamann U, Schu ¨rmann J, Schwab M (1991) The N-
Myc oncoprotein is associated in vivo with the phosphoprotein Max(p20/22) in
human neuroblastoma cells. EMBO J 10: 3703–3712.
47. Wakamatsu Y, Watanabe Y, Nakamura H, Kondoh H (1997) Regulation of the
neural crest cell fate by N-myc: promotion of ventral migration and neuronal
differentiation. Development 124: 1953–1962.
48. Blackwood EM, Lu ¨scher B, Kretzner L, Eisenman RN (1991) The Myc:Max
protein complex and cell growth regulation. Cold Spring Harb Symp Quant Biol
56: 109–117.
49. Hu H, Du L, Nagabayashi G, Seeger RC, Gatti RA (2010) ATM is down-
regulated by N-Myc-regulated microRNA-421. Proc Natl Acad Sci 107:
1506–1511.
50. Cotterman R, Knoepfler PS (2009) N-Myc Regulates Expression of Pluripotency
Genes in Neuroblastoma Including lif, klf2, klf4, and lin28b. PLoS ONE 4:
e5799.
51. Auvinen M, Ja ¨rvinen K, Hotti A, Okkeri J, Laitinen J, et al. (2003)
Transcriptional regulation of the ornithine decarboxylase gene by c-Myc/
Max/Mad network and retinoblastoma protein interacting with c-Myc.
Int J Biochem Cell Biol 35: 496–521.
52. Perini G, Diolaiti D, Porro A, Della Valle G (2005) In vivo transcriptional
regulation of N-Myc target genes is controlled by E-box methylation. Proc Natl
Acad Sci 102: 12117–12122.
53. Shimono A, Okuda T, Kondoh H (1999) N-myc-dependent repression of Ndr1,
a gene identified by direct subtraction of whole mouse embryo cDNAs between
wild type and N-myc mutant. Mech Dev 83: 39–52.
54. Dewar BJ, Bradford BU, T RG (2002) Nicotine increases hepatic oxygen uptake
in the isolated perfused rat liver by inhibiting glycolysis. J Pharmacol Exp Ther
301: 930–937.
55. Toyohara J, Ishiwata K, Sakata M, Wu J, Nishiyama S, et al. (2010) In vivo
evaluation of alpha7 nicotinic acetylcholine receptor agonists [11C]A-582941
and [11C]A-844606 in mice and conscious monkeys. PLoS ONE 5: e8961.
56. Sweileh W, Wenberg K, Xu J, Forsayeth J, Hardy S, et al. (2000) Multistep
expression and assembly of neuronal nicotinic receptors is both host-cell-
and receptor-subtype-dependent. Brain Res Mol Brain Res 75: 293–
302.
57. Mayerhofer A, Fritz S (2002) Ovarian acetylcholine and muscarinic receptors:
Hints of a novel intrinsic ovarian regulatory system. Microsc Res Tech 59:
503–508.
58. Mayerhofer A, Dimitrijevic N, Kunz L (2003) The expression and biological role
of the non-neuronal cholinergic system in the ovary. Life Sci 72: 2039–2045.
59. Schuller HM (2007) Nitrosamines as nicotinic receptor ligands. Life Sciences 80:
2274–2280.
60. Liu Q, Zhang J, Zhu H, Qin C, Chen Q, et al. (2007) Dissecting the signaling
pathway of nicotine-mediated neuroprotection in a mouse Alzheimer disease
model. FASEB J 21: 61–73.
61. Valentine JD, Matta SG, Sharp BM (1996) Nicotine-induced cFos expression in
the hypothalamic paraventricular nucleus is dependent on brainstem effects:
correlations with cFos in catecholaminergic and noncatecholaminergic neurons
in the nucleus tractus solitarius. Endocrinology 137: 622–630.
62. Mi-Hyeon J, Min-Chul S, Hong K, Ee-Hwa K, Chang-Ju K (2003) Dose-
dependence of the effect of nicotine on c-Fos expression in the hippocampus of
young rats. Neurosci Res Commun 32: 11–19.
63. Craig WY (1993) The effect of compounds associated with cigarette smoking on
the secretion of lipoprotein lipid by HepG2 cells. Biochim Biophys Acta 1165:
249–258.
64. Hu M, Liu Q-s, Chang KT, Berg DK (2002) Nicotinic Regulation of CREB
Activation in Hippocampal Neurons by Glutamatergic and Nonglutamatergic
Pathways. Mol Cell Neurosci 21: 616–625.
65. Smith JR, Osborne TF, Brown MS, Goldstein JL, Gil G (1988) Multiple sterol
regulatory elements in promoter for hamster 3-hydroxy-3-methylglutaryl-
coenzyme A synthase. J Biol Chem 263: 18480–18487.
66. Osborne TF (1991) Single nucleotide resolution of sterol regulatory region in
promoter for 3-hydroxy-3-methylglutaryl coenzyme A reductase. J Biol Chem
266: 13947–13951.
67. Vallett SM, Sanchez HB, Rosenfeld JM, Osborne TF (1996) A Direct Role for
Sterol Regulatory Element Binding Protein in Activation of 3-Hydroxy-3-
methylglutaryl Coenzyme A Reductase Gene. J Biol Chem 271: 12247–
12253.
68. Ngo TT, Bennett MK, Bourgeois AL, Toth JI, Osborne TF (2002) A Role for
Cyclic AMP Response Element-binding Protein (CREB) but Not the Highly
Similar ATF-2 Protein in Sterol Regulation of the Promoter for 3-Hydroxy-
3-Methylglutaryl Coenzyme A Reductase. J Biol Chem 277: 33901–
33905.
69. Lemaire-Ewing S, Berthier A, Royer M, Logette E, Corcos L, et al. (2009) 7b-
Hydroxycholesterol and 25-hydroxycholesterol-induced interleukin-8 secretion
involves a calcium-dependent activation of c-fos via the ERK1/2 signaling
pathway in THP-1 cells. Cell Biol Toxicol 25: 127–139.
70. Rinn JL, Rozowsky JS, Laurenzi IJ, Petersen PH, Zou K, et al. (2004) Major
Molecular Differences between Mammalian Sexes Are Involved in Drug
Metabolism and Renal Function. Dev Cell 6: 791–800.
71. Gauthier BR (1998) Characterization of a Novel Liver-Specific Protein/DNA
Binding Site in the Human HMG CoA Reductase Promoter. Biochem Biophys
Res Commun 247: 280–286.
72. Tacer KF, Haugen TB, Baltsen M, Debeljak N, Rozman D (2002) Tissue-
specific transcriptional regulation of the cholesterol biosynthetic pathway leads
to accumulation of testis meiosis-activating sterol (T-MAS). J Lipid Res 43:
82–89.
73. Di Croce L, Vicent GP, Pecci A, Bruscalupi G, Trentalance A, et al. (1999) The
Promoter of the Rat 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Gene
Contains a Tissue-Specific Estrogen-Responsive Region. Mol Endocrinol 13:
1225–1236.
74. Chen GP, Yao L, Lu X, Li L, Hu SJ (2008) Tissue-specific effects of atorvastatin
on 3-hydroxy-3-methylglutarylcoenzyme A reductase expression and activity in
spontaneously hypertensive rats. Acta Pharmacol Sin 29: 1181–1186.
75. Mahapatra NR, Mahata M, Datta AK, Gerdes HH, Huttner WB, et al. (2000)
Neuroendocrine Cell Type-Specific and Inducible Expression of the Chromo-
granin B Gene: Crucial Role of the Proximal Promoter. Endocrinology 141:
3668–3678.
76. Hsu M, Muchova L, Morioka I, Wong RJ, Schro ¨der H, et al. (2006) Tissue-
specific effects of statins on the expression of heme oxygenase-1 in vivo. Biochem
Biophys Res Commun 343: 738–744.
77. Fielding CJ, Fielding PE (2001) Cellular cholesterol efflux. Biochim Biophys Acta
1533: 175–189.
78. Bocan TM, Ferguson E, McNally W, Uhlendorf PD, Mueller SB, et al. (1992)
Hepatic and nonhepatic sterol synthesis and tissue distribution following
administration of a liver selective HMG-CoA reductase inhibitor, CI-981:
comparison with selected HMG-CoA reductase inhibitors. Biochim Biophys
Acta 1123: 133–144.
79. Parker RA, Clark RW, Sit SY, Lanier TL, Grosso RA, et al. (1990) Selective
inhibition of cholesterol synthesis in liver versus extrahepatic tissues by HMG-
CoA reductase inhibitors. J Lipid Res 31: 1271–1282.
80. Jurevics HA, Morell P (1994) Sources of cholesterol for kidney and nerve during
development. J Lipid Res 35: 112–120.
Hmgcr Polymorphisms Regulate Gene Expression
PLoS ONE | www.plosone.org 15 January 2011 | Volume 6 | Issue 1 | e1666181. Turley SD, Andersen JM, Dietschy JM (1981) Rates of sterol synthesis
and uptake in the major organs of the rat in vivo. J Lipid Res 22: 551–
569.
82. Friese RS, Gayen JR, Mahapatra NR, Schmid-Schonbein GW, O’Connor DT,
et al. (2010) Global metabolic consequences of the chromogranin A-null model
of hypertension: transcriptomic detection, pathway identification, and experi-
mental verification. Physiol Genomics 40: 195–207.
Hmgcr Polymorphisms Regulate Gene Expression
PLoS ONE | www.plosone.org 16 January 2011 | Volume 6 | Issue 1 | e16661